Report cover image

Transient Ischemic Attack Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20147074

Description

Transient ischemic attack, also known as a mini stroke, is characterized by a temporary blockage of blood flow to the brain. It can cause stroke-like symptoms, lasting for a few minutes to a few hours. Various studies indicate the annual incidence of transient ischemic attack to be about 0.42 to 1.22 per 1000 person-years, with the incidence increasing with age. The growing cases of transient ischemic attacks are highlighting the need for new drugs that can address the underlying causes and reduce the risk of progression.

Report Coverage

The Transient Ischemic Attack Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into transient ischemic attack drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for transient ischemic attack. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The transient ischemic attack pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from transient ischemic attack.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to transient ischemic attack.

Transient Ischemic Attack Drug Pipeline Outlook

Transient ischemic attack causes a temporary disruption in the blood supply to a part of the brain. The transient episode of neurological dysfunction can resolve within minutes to hours. Transient ischemic attack needs prompt treatment as it indicates a warning sign of a possible future stroke. Common symptoms include a dropped face, weakness or numbness in one arm, slurred speech, and dizziness, among others.

Treatment for a transient ischemic attack consists of medication like statins and blood thinners that can help prevent a further episode. Popular anticoagulants include edoxaban, apixaban, dabigatran, warfarin, and rivaroxaban. However, the risk of bleeding remains a significant side effect for all anticoagulants. Thus, the limited availability of targeted and effective treatments with a better safety profile reflects a gap in patient care, which can be bridged through the development of more specialized drugs in the pipeline.

Transient Ischemic Attack – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of transient ischemic attack drugs based on several segmentations including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Peptides
  • Oligonucleotides
  • Biologics
By Route of Administration
  • Oral
  • Parenteral
  • Others
Transient Ischemic Attack – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase III covers a major share of the total clinical trials for transient ischemic attacks.

Transient Ischemic Attack – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the transient ischemic attack pipeline analysis include small molecules, peptides, oligonucleotides, and biologics. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for transient ischemic attacks.

Transient Ischemic Attack Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the transient ischemic attack drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in transient ischemic attack clinical trials:
  • Janssen Research & Development, LLC
  • Bayer
  • Ischemia Care LLC
  • Bristol Myers Squibb Company (BMS)
  • Novo Nordisk A/S
Transient Ischemic Attack – Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: Asundexian (BAY2433334)

Sponsored by Bayer, the objective of this Phase III, multicenter, placebo-controlled clinical trial is to evaluate the efficacy of oral FXIa inhibitor, asundexian, for the prevention of ischemic stroke in male and female participants (aged 18 years and above) following a high-risk transient ischemic attack or acute non-cardioembolic ischemic stroke. The study is expected to be completed by October 2025 and has around 12300 participants.

Drug: Milvexian

Janssen Research & Development, LLC is conducting a Phase III clinical trial aimed at investigating the safety and efficacy of milvexian (an oral factor XIa inhibitor) compared to placebo for stroke prevention after a high-risk transient ischemic attack or an acute ischemic stroke. The interventional study has enrolled an estimated 15000 subjects and is expected to be completed by December 2026.

Reasons To Buy This Report

The Transient Ischemic Attack Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for transient ischemic attack. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within transient ischemic attack pipeline insights.

Key Questions Answered in the Transient Ischemic Attack – Pipeline Insight Report
  • What is the current landscape of transient ischemic attack pipeline drugs?
  • How many companies are developing transient ischemic attack drugs?
  • How many phase III and phase IV drugs are currently present in transient ischemic attack pipeline drugs?
  • Which companies/institutions are leading the transient ischemic attack drug development?
  • What is the efficacy and safety profile of transient ischemic attack pipeline drugs?
  • What are the opportunities and challenges present in the transient ischemic attack drug pipeline landscape?
  • Which company is conducting major trials for transient ischemic attack drugs?
  • What geographies are covered for transient ischemic attack clinical trials?
  • What are emerging trends in transient ischemic attack clinical trials?
Related Reports

Transient Ischemic Attack Disease Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Transient Ischemic Attack
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Transient Ischemic Attack
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Transient Ischemic Attack: Epidemiology Snapshot
5.1 Transient Ischemic Attack Incidence by Key Markets
5.2 Transient Ischemic Attack – Patients Seeking Treatment in Key Markets
6 Transient Ischemic Attack: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Transient Ischemic Attack: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Transient Ischemic Attack, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Transient Ischemic Attack Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Transient Ischemic Attack Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Asundexian (BAY2433334)
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: Semaglutide Auto-Injector
10.2.3 Drug: Milvexian
10.2.4 Other Drugs
11 Transient Ischemic Attack Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Ticagrelor 60 + Aspirin, Drug: Ticagrelor 90 + aspirin
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Other Drugs
12 Transient Ischemic Attack Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug 1
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Transient Ischemic Attack Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Transient Ischemic Attack, Key Drug Pipeline Companies
14.1 Janssen Research & Development, LLC
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Bayer
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Ischemia Care LLC
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Bristol Myers Squibb Company (BMS)
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Novo Nordisk A/S
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us